The global respiratory drug market is projected to exceed sales of $44 billion by 2010, according to market research firm Kalorama Information. As the incidence of lung and breathing-related illnesses ...
Muscle relaxants are a necessary part of anesthesia during certain major operations. Studies have, however, hinted at respiratory risks connected with these drugs. A major new study has confirmed the ...
In early April, Pfizer announced a $525 million acquisition of ReViral’s novel therapy for respiratory syncytial virus (RSV). Since then, RSV therapies have garnered renewed global attention. However, ...
Human Respiratory Syncytial Virus Drugs Dominated by Synagis, the only Approved Drug in the Market: Technavio Technavio publishes a new market research report on the global human respiratory syncytial ...
A new study from researchers at Columbia University Vagelos College of Physicians and Surgeons shows that a drug given to some pregnant women to prevent severe respiratory ailments in preterm newborns ...
May 7 (UPI) --Anakinra, a drug developed to treat rheumatoid arthritis, or RA, might help patients who developed acute respiratory distress syndrome caused by COVID-19, a small study published ...
MedPage Today on MSN
Common Antibiotic Tied to Acute Respiratory Failure in Younger Patients
The 30-day risk of a hospital visit for acute respiratory failure was higher among healthy adolescents and young adults ...
GlaxoSmithKline has terminated (PDF) 11 projects over the past 12 months. The respiratory franchise bore the brunt of the cuts at a time when some GSK staff were questioning the wisdom of investing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback